Swiss - Delayed Quote CHF
Addex Therapeutics Ltd (ADXN.SW)
As of 10:04 AM GMT+1. Market Open.
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
829.9410
1,612.9530
1,422.4380
2,916.3080
3,612.8190
Operating Expense
12,034.9260
11,894.3680
21,942.1660
18,422.2220
15,856.0930
Operating Income
-11,204.9850
-10,281.4150
-20,519.7280
-15,505.9140
-12,243.2740
Net Non Operating Interest Income Expense
14.0600
42.3570
-19.6460
-57.6900
-34.1970
Other Income Expense
-665.9520
-317.2850
-264.3600
211.6930
-581.1280
Pretax Income
-11,856.7610
-10,556.2270
-20,804.2130
-15,351.9140
-12,858.5990
Net Income Common Stockholders
4,317.5870
-10,556.2270
-20,804.2130
-15,351.9140
-12,858.5990
Diluted NI Available to Com Stockholders
4,317.5870
-10,556.2270
-20,804.2130
-15,351.9140
-12,858.5990
Basic EPS
0.04
-0.14
-0.46
-0.45
-0.48
Diluted EPS
0.00
-0.14
-0.46
-0.45
-0.48
Basic Average Shares
89,902.1330
74,307.6350
45,184.8650
34,119.6660
26,681.7740
Diluted Average Shares
94,518.8000
74,307.6350
45,184.8650
34,119.6660
26,681.7740
Total Operating Income as Reported
-11,204.8690
-10,281.2990
-20,520.2070
-15,505.9170
-12,243.2740
Rent Expense Supplemental
--
35.5670
47.2830
37.5120
12.0000
Total Expenses
12,034.9260
11,894.3680
21,942.1660
18,422.2220
15,856.0930
Net Income from Continuing & Discontinued Operation
4,317.5870
-10,556.2270
-20,804.2130
-15,351.9140
-12,858.5990
Normalized Income
-11,721.5580
-10,238.9420
-20,539.8530
-15,563.6070
-12,277.4710
Interest Income
35.8670
63.9640
29.2510
5.3220
35.3050
Interest Expense
21.8070
21.6070
48.8970
63.0120
69.5020
Net Interest Income
14.0600
42.3570
-19.6460
-57.6900
-34.1970
EBIT
-11,834.9540
-10,534.6200
-20,755.3160
-15,288.9020
-12,789.0970
EBITDA
-11,419.5580
-10,228.6680
-20,432.1720
-14,941.2890
-12,410.3430
Reconciled Depreciation
337.5080
305.9520
323.1440
347.6130
378.7540
Net Income from Continuing Operation Net Minority Interest
-11,856.7610
-10,556.2270
-20,804.2130
-15,351.9140
-12,858.5990
Total Unusual Items Excluding Goodwill
-135.2030
-317.2850
-264.3600
211.6930
-581.1280
Total Unusual Items
-135.2030
-317.2850
-264.3600
211.6930
-581.1280
Normalized EBITDA
-11,284.3550
-9,911.3830
-20,167.8120
-15,152.9820
-11,829.2150
12/31/2020 - 5/22/2007
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
SPEX.SW Spexis AG
0.0570
0.00%
5CV.DE CureVac N.V.
2.6260
+0.08%
VVY.AS Vivoryon Therapeutics N.V.
2.2100
+0.91%
NWRN.SW Newron Pharmaceuticals S.p.A.
7.90
+1.54%
MOLN.SW Molecular Partners AG
5.27
+1.35%
MNOV MediciNova, Inc.
1.5700
+0.64%
SANN.SW Santhera Pharmaceuticals Holding AG
8.60
-2.27%
IDIA.SW Idorsia Ltd
1.0080
+5.00%
RLF.SW Relief Therapeutics Holding SA
5.80
-0.68%
FDMT 4D Molecular Therapeutics, Inc.
8.28
-0.84%